European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A.; Baccarani, M.; Silver, R.; Schiffer, C.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Deininger, M.; Guilhot, F.; Hjorth-Hansen, H.; Hughes, T.; Janssen, J.; Kantarjian, H.; Kim, Dong-Kee; Larson, R.; Lipton, J.; Mahon, F.; Mayer, J.; Nicolini, F.; Niederwieser, D.; Pane, F.; Radich, J.; Réa, D.; Richter, J.; Rosti, G.; Rousselot, P.; Saglio, G.; Saussele, S.; Soverini, S.; Steegmann, J.; Turkina, A.; Zaritskey, A.; Hehlmann, Ruediger

doi:10.1038/s41375-020-0776-2

Public

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Shared by NobleBlocks on Mar 3, 2020 • 12:00 AM UTC

Authors:

A. Hochhaus

M. Baccarani

R. Silver

Abstract

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remissio...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!